Jakob D Allen1, Marcel J Casavant1,2,3, Henry A Spiller2,3, Thiphalak Chounthirath1, Nichole L Hodges1, Gary A Smith4,3. 1. Center for Injury Research and Policy of the Research Institute at Nationwide Children's Hospital, Columbus, Ohio. 2. Central Ohio Poison Center, Columbus, Ohio; and. 3. Department of Pediatrics, The Ohio State University College of Medicine, Columbus, Ohio. 4. Center for Injury Research and Policy of the Research Institute at Nationwide Children's Hospital, Columbus, Ohio; gary.smith@nationwidechildrens.org.
Abstract
OBJECTIVES: This study analyzes and compares exposures to prescription opioids among children and adolescents younger than 20 years old in the United States. METHODS: Data from the National Poison Data System for 2000 through 2015 were analyzed. RESULTS: Poison control centers received reports of 188 468 prescription opioid exposures among children aged <20 years old from 2000 through 2015. The annual number and rate of exposures increased early in the study period, but declined after 2009, except for buprenorphine exposures, which increased during the last 3 study years. Hydrocodone accounted for the largest proportion of exposures (28.7%), and 47.1% of children exposed to buprenorphine were admitted to a health care facility (HCF). The odds of being admitted to an HCF were higher for teenagers than for children aged 0 to 5 years (odds ratio [OR]: 2.86; 95% confidence interval [CI]: 2.78-2.94) or children aged 6 to 12 years (OR: 6.62; 95% CI: 6.06-7.02). Teenagers also had greater odds of serious medical outcomes than did children aged 0 to 5 years (OR: 3.03; 95% CI: 2.92-3.15) or children aged 6 to 12 years (OR: 4.59; 95% CI: 4.21-5.00). The rate of prescription opioid-related suspected suicides among teenagers increased by 52.7% during the study period. CONCLUSIONS: Prescription opioid-related HCF admissions and serious medical outcomes were higher among teenagers. Contrary to trends for other prescription opioids, exposures to buprenorphine have increased in recent years; children aged 0 to 5 years accounted for almost 90% of buprenorphine exposures. These findings indicate that additional prevention efforts are needed.
OBJECTIVES: This study analyzes and compares exposures to prescription opioids among children and adolescents younger than 20 years old in the United States. METHODS: Data from the National Poison Data System for 2000 through 2015 were analyzed. RESULTS: Poison control centers received reports of 188 468 prescription opioid exposures among children aged <20 years old from 2000 through 2015. The annual number and rate of exposures increased early in the study period, but declined after 2009, except for buprenorphine exposures, which increased during the last 3 study years. Hydrocodone accounted for the largest proportion of exposures (28.7%), and 47.1% of children exposed to buprenorphine were admitted to a health care facility (HCF). The odds of being admitted to an HCF were higher for teenagers than for children aged 0 to 5 years (odds ratio [OR]: 2.86; 95% confidence interval [CI]: 2.78-2.94) or children aged 6 to 12 years (OR: 6.62; 95% CI: 6.06-7.02). Teenagers also had greater odds of serious medical outcomes than did children aged 0 to 5 years (OR: 3.03; 95% CI: 2.92-3.15) or children aged 6 to 12 years (OR: 4.59; 95% CI: 4.21-5.00). The rate of prescription opioid-related suspected suicides among teenagers increased by 52.7% during the study period. CONCLUSIONS: Prescription opioid-related HCF admissions and serious medical outcomes were higher among teenagers. Contrary to trends for other prescription opioids, exposures to buprenorphine have increased in recent years; children aged 0 to 5 years accounted for almost 90% of buprenorphine exposures. These findings indicate that additional prevention efforts are needed.
Authors: James A Feinstein; Jonathan Rodean; Matt Hall; Stephanie K Doupnik; James C Gay; Jessica L Markham; Jessica L Bettenhausen; Julia Simmons; Brigid Garrity; Jay G Berry Journal: Pediatrics Date: 2019-06 Impact factor: 7.124
Authors: Jing Wang; Steven A Sumner; Thomas R Simon; Alex E Crosby; Francis B Annor; Elizabeth Gaylor; Likang Xu; Kristin M Holland Journal: JAMA Psychiatry Date: 2020-07-01 Impact factor: 21.596
Authors: Calista M Harbaugh; Jay S Lee; Hsou Mei Hu; Sean Esteban McCabe; Terri Voepel-Lewis; Michael J Englesbe; Chad M Brummett; Jennifer F Waljee Journal: Pediatrics Date: 2017-12-04 Impact factor: 7.124
Authors: Terri Voepel-Lewis; Frances A Farley; John Grant; Alan R Tait; Carol J Boyd; Sean Esteban McCabe; Monica Weber; Calista M Harbagh; Brian J Zikmund-Fisher Journal: Pediatrics Date: 2020-01 Impact factor: 7.124
Authors: Cecilia P Chung; Stephen Todd Callahan; William O Cooper; William D Dupont; Katherine T Murray; Andrew D Franklin; Kathi Hall; Judith A Dudley; Charles Michael Stein; Wayne A Ray Journal: Pharmacoepidemiol Drug Saf Date: 2019-08-16 Impact factor: 2.890
Authors: Hendrée E Jones; Abdul Ssubor Momand; Brian Morales; Thom Browne; Nicolas Poliansky; Diego Ruiz; Mercedez Aranguren; Silvina Sanchez; Valeria Fratto; Kevin E O'Grady Journal: J Child Adolesc Subst Abuse Date: 2020-05-20